Chadbourne & Parke represented the shareholders of ООО AnviLab in the sale of 100% of the company to Protek Group for $60 million.
AnviLab owns the rights for such pharmaceutical brands as Antigrippin-Maximum, Gepaguard, Influnet and is the legal owner of the ANVI Laboratory brand. The assets acquired under the transaction will pass into management of Protek Group whose key company in the production segment is CJSC Farmfirma Sotex.
Chadbourne advised the shareholders of Laboratory ANVI in connection with negotiations with potential buyers and the sale of the company to Protek. Working for Chadbourne on the deal were London office international partner Konstantin Osipov, London partner Charez Golvala and associates Yadviga Pavlovich in Moscow and Alexandra Neovius in London.
Protek Group is one of the largest vertically integrated pharmaceutical companies in Russia. AnviLab is the owner of over 40 trademarks and the holder of patents for 13 inventions, including one of the first Russian anti-cold combination drugs, manufactured under Antigrippin brand. The Company ranks 25th among the Russian drug manufacturers.
